Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...
Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results